Skinvisible (SKVI) Revenue Growth (3y) (2013 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.02 Bn | 629.26 Bn | 17.26 Bn | 5.56% |
| 2 | AbbVie | 443.38 Bn | 436.81 Bn | 12.70 Bn | 7.01% |
| 3 | Merck | 368.22 Bn | 361.07 Bn | 12.21 Bn | 3.37% |
| 4 | Novartis Ag | 270.16 Bn | 262.47 Bn | 11.24 Bn | 8.00% |
| 5 | Pfizer | 158.63 Bn | 146.93 Bn | 10.94 Bn | 4.95% |
| 6 | Sanofi | 52.92 Bn | 45.54 Bn | 10.79 Bn | 7.50% |
| 7 | Revolution Medicines | 44.49 Bn | 44.49 Bn | - | - |
| 8 | Incyte | 25.22 Bn | 20.69 Bn | 1.57 Bn | 20.59% |
| 9 | United Therapeutics | 21.17 Bn | 18.51 Bn | 683.80 Mn | 9.51% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 0.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00% |
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | -18.73% |
| Jun 30, 2025 | -71.00% |
| Mar 31, 2025 | -56.32% |
| Dec 31, 2024 | -72.96% |
| Sep 30, 2024 | -64.46% |
| Jun 30, 2024 | -74.08% |
| Mar 31, 2024 | -25.42% |
| Dec 31, 2023 | -45.79% |
| Sep 30, 2023 | 23.83% |
| Jun 30, 2023 | -64.42% |
| Mar 31, 2023 | -32.21% |
| Dec 31, 2022 | -22.61% |
| Sep 30, 2022 | -6.22% |
| Jun 30, 2022 | 152.61% |
| Mar 31, 2022 | 92.82% |
| Dec 31, 2021 | 170.64% |
| Sep 30, 2021 | 81.37% |